Heron Therapeutics (HRTX) Expected to Announce Earnings on Thursday

Heron Therapeutics (NASDAQ:HRTX) is expected to post its quarterly earnings results before the market opens on Thursday, February 27th. Analysts expect Heron Therapeutics to post earnings of ($0.03) per share and revenue of $37.37 million for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Heron Therapeutics Stock Down 5.1 %

Shares of HRTX stock opened at $1.68 on Wednesday. The stock has a market cap of $255.52 million, a PE ratio of -9.33 and a beta of 1.60. The business has a 50-day simple moving average of $1.66 and a 200-day simple moving average of $1.71. Heron Therapeutics has a 52-week low of $1.04 and a 52-week high of $3.93.

Wall Street Analyst Weigh In

HRTX has been the topic of several research analyst reports. StockNews.com lowered Heron Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 29th. Needham & Company LLC reiterated a “buy” rating and set a $4.00 target price on shares of Heron Therapeutics in a research report on Wednesday, December 4th.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.